STOCK TITAN

Aeterna Zentaris Inc. - $AEZS STOCK NEWS

Welcome to our dedicated page for Aeterna Zentaris news (Ticker: $AEZS), a resource for investors and traders seeking the latest updates and insights on Aeterna Zentaris stock.

Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZS) is a global biopharmaceutical company specializing in endocrine therapy and oncology. With a robust track record in drug discovery, development, and commercialization, the company focuses on addressing significant unmet medical needs. Aeterna Zentaris' flagship product, macimorelin (marketed as Macrilen® in the U.S. and Ghryvelin™ in Europe), is the first and only FDA and European Commission-approved oral test for diagnosing adult growth hormone deficiency (AGHD). The company is actively pursuing the extension of macimorelin’s application for diagnosing childhood-onset growth hormone deficiency (CGHD), with the Phase 3 DETECT trial nearing completion.

Recently, Aeterna Zentaris announced a definitive agreement to merge with Ceapro Inc. The merger, expected to close in the second quarter of 2024, aims to leverage Ceapro's revenue-generating cosmeceutical and nutraceutical products, such as oat beta glucan and avenanthramides. The combined entity is poised to generate stable cash flow, diversify its product pipeline, enhance research and development capabilities, and strengthen its market presence in both North America and Europe.

The company remains committed to developing an array of therapeutic assets, including treatments for neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism, and amyotrophic lateral sclerosis (ALS). Aeterna Zentaris is well-capitalized, with a strategic plan to advance innovative products and deliver sustained value to its shareholders.

Rhea-AI Summary

Aeterna Zentaris (NASDAQ: AEZS) has announced the clinical completion of its Phase 3 DETECT-trial, which investigates the efficacy and safety of macimorelin for diagnosing Childhood Onset Growth Hormone Deficiency (CGHD). The trial, which involved 100 pediatric patients in Europe and North America, concluded with the last patient visit on June 13, 2024. The company plans to release top-line data and full study results in Q3 2024. Gilles Gagnon, the CEO, emphasized that the successful completion of this trial marks a significant milestone, potentially expanding the use of macimorelin as a diagnostic tool in pediatric endocrinology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
none
-
Rhea-AI Summary

Aeterna Zentaris (NASDAQ: AEZS, TSX: AEZS) and Ceapro (TSX-V: CZO, OTCQX: CRPOF) have completed their all-stock merger announced in December 2023. The new entity, yet to be named, aims to leverage diversified product pipelines, combining financial and operational resources for enhanced R&D capabilities. The merger will drive development in areas like oat beta glucan and avenanthramides, while macimorelin revenues will support high-potential products. Post-merger, Aeterna's board includes eight directors. Ceapro shares will be delisted from the TSX Venture Exchange, and Ceapro shareholders will receive 0.02360 Aeterna shares per Ceapro share. Ceapro aims to cease being a reporting issuer under Canadian laws.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.35%
Tags
-
Rhea-AI Summary

Aeterna Zentaris (NASDAQ: AEZS) announced an application to extend the deadline for its annual meeting of shareholders to July 31, 2024. The hearing is scheduled for June 3, 2024, before the Ontario Superior Court of Justice. The extension aims to finalize a transaction with Ceapro, allowing former Ceapro shareholders to vote at the meeting. The meeting will cover votes on the new company name and director nominees. The Toronto Stock Exchange has approved this extension. Additionally, the redemption date for due bills related to a prior warrant issuance is set for June 3, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.12%
Tags
none
Rhea-AI Summary

Aeterna Zentaris has finalized details of its merger with Ceapro. On May 3, 2024, Aeterna completed a 1-for-4 reverse stock split. Ceapro shareholders will receive 0.02360 of a post-split Aeterna share for each Ceapro share held. Aeterna shareholders on record by May 29, 2024, will get 0.47698 of a warrant per share on May 31, 2024. These shares will trade with a due bill from May 29 to May 31, 2024, ensuring buyers receive warrants. Ex-distribution trading starts on June 3, 2024. The due bill redemption is on June 4, 2024. Shareholders need to take no action to receive warrants, which will be managed electronically. The merger is expected to close on or about June 3, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
none
-
Rhea-AI Summary

Aeterna Zentaris (NASDAQ: AEZS) reported its Q1 2024 financial results, highlighting a cash position of $29.5 million as of March 31, 2024. The company reported a net loss of $5.8 million, compared to a $4.3 million loss in Q1 2023. This increased loss is attributed to a $2.1 million revenue drop and a $1.2 million rise in selling, general, and administrative expenses, mostly due to merger-related costs. The company successfully completed recruitment for its DETECT-trial, with results expected in Q3 2024. The merger with Ceapro Inc. is anticipated to close in Q2 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.06%
Tags
-
Rhea-AI Summary

Aeterna Zentaris Inc. announces the effective date of the share consolidation, reducing the number of common shares by merging with Ceapro Inc. The consolidation will result in one post-consolidation common share for every four pre-consolidation common shares. The company's transfer agent will provide instructions for shareholders on trading post-consolidation common shares on the TSX and Nasdaq Capital Market on May 3, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.18%
Tags
none
Rhea-AI Summary
Aeterna Zentaris Inc. and Ceapro Inc. have received final court approval for their all-stock merger of equals transaction. The Transaction is expected to be completed in the second quarter of 2024, pending necessary approvals and conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.29%
Tags
-
Rhea-AI Summary
Aeterna Zentaris Inc. completes enrollment in pivotal Phase 3 trial, reports $34.0 million cash, and announces merger with Ceapro, Inc. Financial results show a net loss decrease in Q4 2023 compared to 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
-
Rhea-AI Summary
Aeterna Zentaris Inc. and Ceapro Inc. announce the approval of their all-stock merger of equals transaction by securityholders. The voting results show strong support for the merger, with Aeterna shareholders approving the transaction by high percentages. The merger is expected to create a sustainable business for delivering value to the biopharma sector and shareholders. The transaction is subject to customary closing conditions and is expected to close in the second quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.51%
Tags
Rhea-AI Summary
Aeterna Zentaris Inc. recommends shareholders vote for the merger with Ceapro Inc. to create a diversified biopharmaceutical company. The merger aims to combine Ceapro's revenue-generating cosmeceutical business with Aeterna's pipeline of higher-margin pharmaceutical products, potentially leading to stable cash flow, diversified product pipeline, and expanded R&D capabilities. The merger is expected to provide a compelling value proposition and lower risk profile for the combined company and shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags

FAQ

What is Aeterna Zentaris Inc. focused on?

Aeterna Zentaris Inc. specializes in endocrine therapy and oncology, focusing on drug discovery, development, and commercialization.

What is macimorelin?

Macimorelin is an oral drug approved by the FDA and European Commission for diagnosing adult growth hormone deficiency. It is also being developed for childhood-onset growth hormone deficiency.

What recent merger has Aeterna Zentaris announced?

Aeterna Zentaris announced a merger with Ceapro Inc., expected to close in the second quarter of 2024, aimed at leveraging Ceapro's revenue-generating cosmeceutical and nutraceutical products.

What are some products offered by Ceapro?

Ceapro produces active ingredients like oat beta glucan and avenanthramides, used in leading skincare brands such as Aveeno and Jergens.

What is the significance of the DETECT trial?

The DETECT trial is a Phase 3 study evaluating macimorelin for diagnosing childhood-onset growth hormone deficiency. Completion is expected in the second quarter of 2024.

What therapeutic areas is Aeterna Zentaris developing products for?

Aeterna Zentaris is developing therapeutic assets for neuromyelitis optica spectrum disorder, Parkinson's disease, hypoparathyroidism, and amyotrophic lateral sclerosis.

What are the financial conditions of Aeterna Zentaris?

As of recent reports, Aeterna Zentaris is well-capitalized, with $34 million in cash as of December 31, 2023, expected to fund operations through 2024 and into 2025.

What strategic advantages will the merger with Ceapro bring?

The merger is expected to create stable cash flow, diversify the product pipeline, enhance research and development capabilities, and strengthen market presence in North America and Europe.

What are the anticipated benefits of the combined company post-merger?

The combined company aims to deliver value by leveraging revenue from existing products, advancing a diversified pipeline, and achieving operational synergies.

Where can I find more information about Aeterna Zentaris?

For more information, visit the company's website at www.zentaris.com and connect with them on LinkedIn and Facebook.

Aeterna Zentaris Inc.

Nasdaq:AEZS

AEZS Rankings

AEZS Stock Data

19.73M
4.85M
3.95%
0.8%
0.45%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
Summerville